Immutep's Eftilagimod Alfa Shows Survival Benefit in Late-Stage Cancer Trials
Event summary
- Immutep's eftilagimod alfa (efti) combined with standard-of-care (SOC) therapies showed a median overall survival (OS) improvement of +7.7 months (p=0.00171) in ALC responders across 5 clinical trials.
- The analysis included 5,922 patients across four cancer indications (NSCLC, HNSCC, MBC, melanoma) and demonstrated broad immune activation linked to clinical benefit.
- Results will be presented at the 2026 ASCO Annual Meeting on May 30, 2026.
- The TACTI-004 Phase III trial in first-line non-small cell lung cancer was discontinued in March 2026 due to futility.
The big picture
Immutep's findings suggest a potential breakthrough in immune activation for late-stage cancer patients, aligning with the broader industry shift towards combination therapies. The results come at a critical juncture as the company navigates the discontinuation of its Phase III TACTI-004 trial, highlighting the challenges of developing novel immunotherapies. The upcoming ASCO presentation will be key in validating these findings and shaping investor sentiment.
What we're watching
- Clinical Validation
- Whether the survival benefit observed in the exploratory analysis can be replicated in future trials, particularly in light of the TACTI-004 futility outcome.
- Regulatory Pathway
- The pace at which Immutep can advance efti through regulatory approvals given the mixed trial results.
- Competitive Positioning
- How Immutep differentiates efti in the crowded immunotherapy space, especially against established PD-1 antagonists.
Related topics